Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Executive Summary: The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026

Same author

The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026

Same author

Long-Term Anifrolumab Treatment Normalizes Hematologic Parameters and Several Serologic Markers in Patients With Systemic Lupus Erythematosus.

ACR open rheumatology·2026

Same author

Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Same author

Real-world experience of anifrolumab treatment in patients with moderate-to-severe SLE: a retrospective study of patients in early access programmes.

Lupus science & medicine·2026

Same author

Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus.

The New England journal of medicine·2026

Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026

Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026

Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026

Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026

Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026

Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 12, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Rituximab biosimilars.

Edward M Vital¹, Jonathan Kay, Paul Emery

¹Leeds Teaching Hospitals NHS Trust, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK. e.m.j.vital@leeds.ac.uk

Expert Opinion on Biological Therapy

|April 23, 2013

Summary

This summary is machine-generated.

Biosimilar rituximab offers potential cost savings for biologics, but manufacturing and regulatory hurdles remain. Rigorous testing ensures safety and efficacy, aiming to make rituximab more accessible.

More Related Videos

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

Related Experiment Videos

Last Updated: May 12, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

Area of Science:

Biotechnology
Immunology
Pharmacology

Background:

Rituximab, a CD20-targeting monoclonal antibody, is widely used for B cell malignancies and autoimmune diseases.
It holds the largest market share among monoclonal antibody therapeutics.
Upcoming patent expiry is driving the development of rituximab biosimilars.

Purpose of the Study:

To review factors influencing rituximab efficacy.
To examine challenges in biosimilar manufacturing and evaluation.
To discuss regulatory aspects and current development status of rituximab biosimilars.

Main Methods:

Literature review encompassing peer-reviewed articles, conference abstracts, and regulatory/industry websites.
Analysis of technical, regulatory, and market factors related to rituximab biosimilars.

Main Results:

Biosimilar development is advancing, driven by the need for cost reduction in biologic therapies.
Technical and regulatory challenges in biosimilar evaluation are being addressed.
Concerns about biosimilar dissimilarities are manageable through comprehensive testing.

Conclusions:

Biosimilar rituximab presents an opportunity to reduce healthcare costs, supported by political and clinical demand.
While concerns exist, robust testing and clear regulations can ensure biosimilar safety and efficacy.
The ultimate impact of rituximab biosimilars hinges on achieving significant cost reductions despite high development expenses.